CJC-1295 without DAC
Lyophilized research reference material. Released with a per-lot Certificate of Analysis. For laboratory research use only.
- All products currently listed on this site are for research purposes ONLY.
- All products sold on this website are intended for research and identification purposes only.
- These products are not intended for human dosing, injections, or ingestion.
- Peptides are strictly for laboratory, academic, or institutional research and not for human or animal consumption.
Research background
CJC-1295 without DAC (also called Modified GRF 1-29) is a tetra-substituted analog of the first 29 residues of growth-hormone-releasing hormone, modified for resistance to enzymatic cleavage but lacking the albumin-binding DAC linker, giving it a shorter duration of action than the DAC form.
It is studied as a GHRH-receptor agonist in research settings; it has no approved indication.
Summary of published scientific literature provided for laboratory research reference only. It is not a claim of safety, efficacy, or suitability for any use, and does not describe or recommend any human or veterinary use.
Selected references
- Frohman LA, et al. Growth hormone-releasing hormone: structure, function, and clinical applications. Endocrine Reviews. 1986;7(3):223-253.
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
- Alba M, et al. Once-daily administration of a GHRH analog. Endocrinology. 2006;147(6):2962-2970.
Trademarks & attribution
CJC-1295 without DAC (Modified GRF 1-29) is a research peptide with no approved trademarked drug product. Catalyst Research Labs is not affiliated with any manufacturer. Supplied as reference material only.
